| Similar Articles |
|---|
 |
The Motley Fool
October 8, 2008
Brian Orelli |
Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.   |
The Motley Fool
March 23, 2009
Brian Orelli |
Which Pharmas Still Have Cash? Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever. |
The Motley Fool
March 31, 2009
Brian Orelli |
Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news. |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
The Motley Fool
January 16, 2009
Brian Orelli |
Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats. |
The Motley Fool
September 2, 2009
Brian Orelli |
Pfizer's Paying $2.3 Billion Again? Oh, Wait, Never Mind. There are 17 articles on the Yahoo! Finance ticker feed announcing or discussing the $2.3 billion settlement Pfizer made with the Department of Justice. |
The Motley Fool
June 11, 2009
Brian Orelli |
Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children. |
The Motley Fool
May 22, 2009
Brian Orelli |
J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs. |
The Motley Fool
December 22, 2006
Stephen Albainy-Jenei |
Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use. |
The Motley Fool
December 3, 2007
Brian Orelli |
More Heartburn From J&J's Natrecor The company takes a $440 million writedown as the heart drug continues to falter. Investors, Johnson & Johnson has a way to go before it can turn things around. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
December 23, 2009
Brian Orelli |
2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
October 9, 2008
Brian Orelli |
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
February 11, 2009
Brian Orelli |
The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder. |
The Motley Fool
March 23, 2009
Brian Orelli |
Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs. |
The Motley Fool
December 14, 2009
Brian Orelli |
Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
March 24, 2009
Brian Orelli |
Taking the F Out of FDA President Barack Obama's nomination for deputy commissioner of the Food and Drug Administration has gotten people talking about the possibility of splitting the food safety portion away from the drug portion of the agency. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
February 26, 2009
Brian Orelli |
Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
April 6, 2009
Brian Orelli |
FDA to Search Engines: You Lose! FDA cracks down on pharma ads, but search engines are the real losers. The FDA wants the drugmakers to stop making claims in sponsored link advertisements. |
The Motley Fool
January 24, 2005
Rich Duprey |
No Taking Chances With Reminyl Johnson & Johnson's daffodil-extract Alzheimer's treatment yanked from market. Shares are off only 1% or so. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
March 14, 2011
Brian Orelli |
This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business. |
The Motley Fool
January 31, 2008
Brian Lawler |
A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing. |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
February 23, 2009
Brian Orelli |
Why Do You Hate Health-Care Companies So Much? Members of Congress plan to introduce a bill that would give patients legal recourse against medical device companies making drug-eluting stents, essentially nullifying a previous Supreme Court decision. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
April 20, 2009
Brian Orelli |
A Cheer and a Boo for Eli Lilly Cost-cutting is nice, but it doesn't slow down the drive toward the patent cliff. Lilly needs to be on the lookout for other partnerships to fill in the upcoming revenue holes. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
August 24, 2007
Brian Orelli |
Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note. |
The Motley Fool
April 15, 2009
Brian Orelli |
Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different. |
The Motley Fool
December 18, 2009
Brian Orelli |
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
